MDM2
MDM2 (MDM2 proto-oncogene, also known as HDM2) is a nuclear-localised RING finger E3 ubiquitin-protein ligase. It targets p53/TP53 for proteasomal degradation and restrains p53-mediated cell cycle arrest and apoptosis. Browse Assay Genie's current range of MDM2 research reagents below, or read on for the biology behind the target.
MDM2 is an E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. It also inhibits p53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding the transcriptional activation domain of these proteins, and it permits the nuclear export of p53. MDM2 acts as an E3 ligase toward itself and ARRB1, and promotes proteasome-dependent, ubiquitin-independent degradation of the retinoblastoma protein RB1.
Beyond p53, MDM2 ubiquitinates a broad set of substrates. These include DAXX, DYRK2, IGF1R and SNAI1, which are directed to proteasomal degradation, as well as DCX, whose loss reduces dendritic spine density of olfactory bulb granule cells, and DLG4, whose degradation is required for AMPA receptor endocytosis. MDM2 also negatively regulates NDUFS1 by retaining it in the cytosol, which lowers complex I activity and supercomplex assembly and increases ROS production and apoptosis. It is a component of the TRIM28/KAP1-MDM2-p53 complex that stabilises p53, and of the TRIM28/KAP1-ERBB4-MDM2 complex that links growth factor and DNA damage response pathways.
The MDM2 gene belongs to the MDM2/MDM4 family and to the HGNC groups of RING finger E3 ubiquitin protein ligases and RANBP2-type zinc fingers. UniProt places the protein in the nucleoplasm, nucleolus and cytoplasm. The gene is itself transcriptionally regulated by p53, and overexpression or amplification of the locus is detected in a variety of cancers. Alternative splicing gives many transcript variants, several of which may be expressed only in tumour cells, and a pseudogene lies on chromosome 2. Earlier names include mouse double minute 2 human homolog and p53-binding protein.
MDM2 degrades p53 and is itself induced by p53, and overexpression or amplification of its locus is seen in many cancers.
As a RING-type E3 ligase that ubiquitinates itself, p53, RB1, DAXX, IGF1R and SNAI1, MDM2 is a model for substrate-specific degradation.
MDM2 inhibits DAXX-mediated apoptosis and, by retaining NDUFS1 in the cytosol, lowers complex I activity and promotes ROS production.
MDM2 ubiquitinates DCX and DLG4, linking it to dendritic spine density and AMPA receptor endocytosis, and joins a complex with ERBB4.
MDM2 is an E3 ubiquitin ligase that ubiquitinates p53, leading to its proteasomal degradation. It also binds the p53 transactivation domain, blocking p53-mediated arrest and apoptosis, and permits p53 nuclear export. It targets other proteins too, including RB1, DAXX, IGF1R, SNAI1, DCX and DLG4.
The HGNC name is MDM2 proto-oncogene, and the UniProt name is E3 ubiquitin-protein ligase Mdm2. Aliases include HDM2 and MGC5370. Earlier names include mouse double minute 2, human homolog of, and p53-binding protein. NCBI notes that alternative splicing yields many transcript variants.
NCBI reports that overexpression or amplification of the MDM2 locus occurs in a variety of cancers, and that the protein can promote tumour formation by targeting suppressors such as p53. A mouse ortholog, Mdm2, exists; check the datasheet of any product for its validated reactivity.
p53 pathway partners, MDM2 substrates and other ubiquitin-proteasome and apoptosis targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q00987; product specifications from Assay Genie datasheets.